Compare Amphastar Pharmaceuticals Inc (AMPH) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MasTec Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while MasTec Inc trades at $273.93 (market cap $21.54B). The key difference: MasTec Inc is far larger — about 24.9× Amphastar Pharmaceuticals Inc's market cap, and MasTec Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MTZ | |
|---|---|---|
Market Cap | $863.95M | $21.54B |
Sector | Health | Technology |
52-Week High | $30.81 | $437.51 |
52-Week Low | $16.87 | $172.51 |
Enterprise Value | $1.26B | $24.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MasTec (MTZ) trades at $272.46, up 5.35% with strong YTD performance of 25.9%, outperforming the S&P 500. The stock shows bearish technical signals but maintains robust fundamentals with record Q2 2026 revenue of $4.37B and 40% EBITDA growth. Recent acquisition of The Superior Group for $1.65B expands critical infrastructure capabilities. The company raised 2026 guidance citing strong infrastructure demand and a record $21.4B backlog.
Despite technical weakness, MasTec's strong earnings momentum and 88.9% analyst buy rating with $447.91 price target suggest significant upside. Key risks include execution of large acquisitions and communications segment delays. The stock offers exposure to infrastructure growth trends but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
